Hospital and advocacy group opposition to state public options could foretell trouble for national single-payer efforts; electronic health records (EHRs) present new opportunities for fraud; the FDA has approved the first generic versions of apixaban (Eliquis).
As individual states increase their efforts to implement public options for residents, insurance companies and hospitals are leading the opposition. Come January, Colorado will vote on a public option which would be managed by private insurers, and could save consumers up to 15% on premiums, according to The Hill. National groups have been rallying against the proposal in Colorado, claiming it is only a matter of time before the impetus behind state reforms reaches the federal level.Software companies used by hospitals to track patients’ medical data have concealed “dangerous flaws” in their electronic health record (EHR) systems, all the while receiving billions of dollars in federal subsidies, according to a Kaiser Health News/Fortune joint investigation. Several whistle blowers revealed instances of fraudulent certification of health technology companies. Hospital chains submitted false claims for EHR stimulus payments, resulting in government lawsuits. General mismanagement of patient data has dire consequences for patients, who could receive incorrect prescriptions as a result.
The FDA has approved 2 generic versions for apixaban (Eliquis), which is used to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, marking the first generic approvals of a direct oral anticoagulant, according to an FDA news release. The approvals were granted to Micro Labs Limited and Mylan Pharmaceuticals Inc. Apixaban is also indicated for the treatment and prevention of deep vein thrombosis (DVT), treatment of pulmonary embolism (PE), and reduction of the risk of recurrent DVT and PE after initial therapy.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen